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Anaphylaxis is a severe, rapidly progressive, life-threatening
allergic reaction. The diagnosis of anaphylaxis is primarily
clinical, and based upon symptoms and signs affecting
multiple organ systems (cardiovascular, respiratory, gastro-
intestinal and/or dermatologic), as well as a detailed his-
tory of the acute episode, antecedent exposures, and past
medical history. Although debate remains over a clinically
useful deﬁnition of anaphylaxis, the National Institute of
Allergy and Infectious Disease (NIAID) and the Food
Allergy and Anaphylaxis Network (FAAN) recently pub-
lished diagnostic criteria to help clinicians recognize the
entire spectrum of manifestations of this potentially fatal
disorder (1).
Food allergy affects about 6% of children <5 yr of age,
and 3–4% of adults in the United States (2). Food-related
reactions include a spectrum of presentations with anaphy-
laxis being the most severe manifestation. Food allergens are
especially concerning because of the potential for certain
allergens to cause reaction upon ﬁrst known ingestion, or to
be highly associated with severe reactions. Food allergy is the
leading cause (among identiﬁed triggers) of anaphylaxis in
children and is responsible for half of reported anaphylaxis
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Abstract
Background: Initial food-allergic reactions are often poorly recognized and under-
treated.
Methods: Parents of food-allergic children were invited to complete an online ques-
tionnaire, designed with Kids with Food Allergies Foundation, about their children’s
ﬁrst food-allergic reactions resulting in urgent medical evaluation.
Results: Among 1361 reactions, 76% (95% CI 74–79%) were highly likely to repre-
sent anaphylaxis based on NIAID/FAAN criteria. Only 34% (95% CI 31–37%) of
these were administered epinephrine. In 56% of these, epinephrine was administered
by emergency departments; 20% by parents; 9% by paramedics; 8% by primary
care physicians; and 6% by urgent care centers. In 26% of these, epinephrine was
given within 15 min of the onset of symptoms; 54% within 30 min; 82% within 1 h;
and 93% within 2 h. Factors associated with a decreased likelihood of receiving epi-
nephrine for anaphylaxis included age <12 months, milk and egg triggers, and
symptoms of abdominal pain and/or diarrhea. Epinephrine was more likely to be
given to asthmatic children and children with peanut or tree nut ingestion prior to
event. Post-treatment, 42% of reactions likely to represent anaphylaxis were referred
to allergists, 34% prescribed and/or given epinephrine auto-injectors, 17% trained
to use epinephrine auto-injectors, and 19% given emergency action plans. Of
patients treated with epinephrine, only half (47%) were prescribed epinephrine auto-
injectors.
Conclusions: Only one-third of initial food-allergic reactions with symptoms of ana-
phylaxis were recognized and treated with epinephrine. Fewer than half of patients
were referred to allergists. There is still a need to increase education and awareness
about food-induced anaphylaxis.
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cases presenting to emergency departments (1, 3–12). The
incidence of food-induced anaphylaxis has been increasing,
particularly within the pediatric population (13–16).
There is limited prior study of the management of anaphy-
laxis in pediatric populations, especially studies that examine
management of anaphylaxis outside the emergency depart-
ment setting. In this survey study, we examined the manage-
ment of food-allergic reactions and anaphylaxis in children
that caused them to be urgently evaluated by medical profes-
sionals for the ﬁrst time, before those children and their par-
ents were familiar with the manifestation and treatment of
those reactions. We hypothesized that food-related anaphy-
laxis is under-recognized and under-managed in children with
initial severe reactions.
Methods
Study design
We developed an internet-based, parental survey study in
conjunction with Kids with Food Allergies Foundation to
examine the management of food-related anaphylaxis in chil-
dren. Kids with Food Allergies Foundation is a national
non-proﬁt food allergy support organization for families rais-
ing children with food allergies. Parents of food-allergic chil-
dren were recruited from website announcements, social
networking posts and targeted membership emails to com-
plete a brief (40 questions, 20 min) online questionnaire
regarding food-related allergic reactions in their children that
necessitated urgent medical evaluation for the ﬁrst time. The
survey collected responses between July 28, 2010 and January
13, 2011.
Only survey responses of food-related allergic reactions of
children under the age of 18 yr that required urgent medical
attention for the ﬁrst time were included. Only respondents
who fully completed surveys were included. All information
collected was de-identiﬁed. The protocol for this study was
approved by the University of Pittsburgh Institutional
Review Board.
Measures
Survey questions included demographics, past medical his-
tory, home medications, family history of allergies, probable
food allergen exposure, time of onset of symptoms, symp-
toms, medical providers, epinephrine treatment, treatment
provided other than epinephrine, admission outcomes, and
discharge instructions concerning the ﬁrst food-allergic reac-
tion that prompted evaluation and care by a medical profes-
sional. In addition to symptoms, participants were asked
about physical examination ﬁndings that they remember
being told by medical staff.
Statistical analysis
Data were analyzed using StataSE 9.2 (College Station, TX,
USA). Anaphylaxis was deﬁned using the National Institute
of Allergy and Infectious Disease (NIAID)/Food Allergy and
Anaphylaxis Network (FAAN) criteria (1). Speciﬁcally, ana-
phylaxis is highly likely if there is an acute onset of an illness
(minutes to several hours) with involvement of the skin/
mucosal tissue and at least one of either respiratory compro-
mise or reduced blood pressure. Alternatively, anaphylaxis is
highly likely if there are two or more of the following that
occur rapidly after exposure to a likely allergen (minutes to
several hours): involvement of the skin-mucosal tissue, respi-
ratory compromise, reduced blood pressure or associated
symptoms, and persistent gastrointestinal symptoms. The
third criterion (low blood pressure after exposure to known
allergen) is not applicable in this study because these were
index reaction, not food allergen. Based on parental reports
of presenting symptoms of these reactions, we identiﬁed a
subset of survey respondents with food-related allergic reac-
tions as highly likely for anaphylaxis.
Descriptive analyses were performed using mean estima-
tions, medians, and binomial proportion estimations. For
binary outcome and exposure variables, odds ratios (OR)
were calculated using binary logistic regression models.
Results
Baseline demographic characteristics and past medical
history
The survey collected 1700 responses. After inclusion and
exclusion criteria were applied, 1361 survey responses quali-
ﬁed for analysis. Nearly all (except 5) reported index reac-
tions occurred between 1990 and 2010. Using NIAID/FAAN
anaphylaxis criteria, we identiﬁed a subset of 1044 responses
of 1361% or 76.7% (95% CI 74.5–79.0%) as highly likely
for anaphylaxis (Table 1).
Mean age at the time of the index reactions was
16 months. Just under half (43.8%) of the patients were
under 1 yr of age. Approximately one-third (35.9%) of the
patients were female. With respect to comorbidities, asthma
was present in 18.4% of the patients, including 20.8% of
those presenting with symptoms highly likely for anaphylaxis,
and 10.4% of those without such symptoms (p < 0.001).
Allergic rhinitis was present in 16.4% of the patients; 18.0%
of those presenting with symptoms likely for anaphylaxis,
and 11.0% of those without such symptoms (p = 0.003).
Atopic dermatitis was present in over half of the patients for
both groups. Earlier in the day prior to the allergic events,
2.3% of the patients had taken asthma rescue medications.
Signiﬁcantly, more patients with likely anaphylaxis were on
asthma controller medications (4.9%), compared with those
without likely anaphylaxis (0.6%) (p < 0.001). Less than
one-tenth of the patients (8.0%) had taken antihistamines
prior to the index reactions, including 9.1% of those with
likely anaphylaxis, and 4.4% of those without anaphylaxis
(Table 1).
Index food-allergic reaction characteristics
Approximately one-third (29.5%) of food-allergic reactions
that required medical attention for the ﬁrst time reported
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peanut as the food trigger; 27.9% in those with likely ana-
phylaxis, and 34.7% in those without likely anaphylaxis
(p = 0.020). Signiﬁcantly, more patients with likely anaphy-
laxis reported milk as the inciting food (35.5%), compared
with those without anaphylaxis (28.4%) (p = 0.019). Eleven
percent of the patients (11.8%) reported tree nut ingestion
prior to the index reaction; 14.2% egg ingestion, 5.1% wheat
ingestion, 3.8% soy ingestion, 1.3% ﬁsh ingestion, and 0.5%
shellﬁsh ingestion (Table 2).
The median time after food ingestion to reported onset of
symptoms for the index reactions was within 30 min. About
half (48.4%) of the index reactions occurred while the child
was eating the inciting food, 79.1% of the reactions occurred
within 30 min after food ingestion, 86.0% within 1 h, 93.9%
within 2 h, 96.6% within 4 h, and 97.7% within 6 h. There
were no signiﬁcant differences between the group with highly
likely anaphylaxis and the group without such symptoms.
Almost all of the patients (93.5%) reported developing
skin and/or mucosal symptoms. A small percentage (3.5%)
of likely anaphylaxis case did not report skin and/or mucosal
symptoms. Over half of the patients (61.8%) had respiratory
symptoms. This included 79.2% of those with likely anaphy-
laxis, compared with only 4.4% of those without likely ana-
phylaxis. One-quarter of the patients (25.4%) reported
cardiovascular symptoms, including 32.1% of those with
likely anaphylaxis, compared with only 3.2% of those with-
out anaphylaxis. Gastrointestinal symptoms were present in
about half of the patients (52.9%), including 66.0% of those
with likely anaphylaxis, and in 9.8% of those without ana-
phylaxis. Biphasic symptoms were present in under one-ﬁfth
of patients (17.2%).
Epinephrine administration and anaphylaxis management
Epinephrine administration information was available in
1300 of 1361 survey responses because of missing data or
respondent uncertainty. Of those, 988/1300 or 76.0% (95%
CI 74.4–79.0%) of index reactions met NIAID/FAAN crite-
ria as highly likely for anaphylaxis. Only 339/988 or 34.3%
(95% CI 31.3–37.3%) of patients with food-induced anaphy-
laxis reported they received epinephrine, compared with
7.7% of patients without anaphylaxis (Fig. 1).
Of the index reactions judged to have anaphylaxis and
administered epinephrine, it was administered by emergency
departments in 56.1% (190/339), pre-hospital by parents in
20.1% (68/339), by paramedics in 9.4% (32/339), by primary
care physicians in 8.3% (28/339), and by urgent care centers
in 6.2% (21/339) of cases.
Table 1 Demographic characteristics and medical history of patients with food-related allergic reactions with and without anaphylaxis
(n = 1361)
Demographics/medical history Anaphylaxis
n (%)
No anaphylaxis
n (%)
Total
n (%)
p*
Total, n (%) 1044 (76.7) 317 (23.3) 1361 (100.0)
Demographics
Mean age (months) 18 12 16 <0.001
Age <1 yr 442 (42.3) 154 (48.6) 596 (43.8) 0.050
Gender (female) 378 (36.2) 110 (34.7) 488 (35.9) 0.624
Medical history
Asthma 217 (20.8) 33 (10.4) 250 (18.4) <0.001
Allergic rhinitis 188 (18.0) 35 (11.0) 223 (16.4) 0.003
Atopic dermatitis 596 (57.1) 195 (61.5) 791 (58.1) 0.162
Eosinophilic esophagitis 33 (3.2) 0 (0.0) 33 (2.4) 0.001
Hymenoptera allergy 6 (0.6) 0 (0.0) 6 (0.4) 0.176
Gastroesophageal reflux 150 (14.4) 26 (8.2) 176 (12.9) 0.004
Medications taken prior to event
Asthma rescue meds 28 (2.7) 3 (1.0) 31 (2.3) 0.070
Asthma controller meds 51 (4.9) 2 (0.6) 53 (3.9) 0.001
Antihistamines 95 (9.1) 14 (4.4) 109 (8.0) 0.007
Gastroesophageal reflux meds 71 (6.8) 16 (5.1) 87 (6.4) 0.264
*The p-value for a chi-square test.
Table 2 Foods ingested that resulted in food-related allergic reac-
tions with and without anaphylaxis (n = 1361)
Foods ingested Anaphylaxis
n (%)
No anaphylaxis
n (%)
Total
n (%)
p*
Total, n (%) 1044 (76.7) 317 (23.3) 1361 (100.0)
Peanut 291 (27.9) 110 (34.7) 401 (29.5) 0.020
Tree nut 133 (12.7) 28 (8.8) 161 (11.8) 0.059
Milk 371 (35.5) 90 (28.4) 461 (33.9) 0.019
Egg 144 (13.8) 49 (15.5) 193 (14.2) 0.457
Wheat 51 (4.9) 19 (6.0) 70 (5.1) 0.434
Soy 38 (3.6) 13 (4.1) 51 (3.8) 0.705
Fish 15 (1.4) 2 (0.6) 17 (1.3) 0.258
Shellfish 7 (0.7) 0 (0.0) 7 (0.5) 0.144
Other 95 (9.1) 43 (13.6) 138 (10.1) 0.021
Unknown 71 (6.8) 20 (6.3) 91 (6.7) 0.759
*The p-value for a chi-square test.
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The median time between development of symptoms and
reported epinephrine administration by all providers com-
bined in likely anaphylaxis cases was between 15 and 30 min.
In the likely anaphylaxis cases, median reported response
time for epinephrine administration was within 15 min by
parents, 15–30 min for paramedics and primary care center,
and 30–60 min for urgent care centers to emergency depart-
ments. Epinephrine was administered within 15 min of the
onset of symptoms in 26.3% of likely anaphylaxis cases,
53.7% within 30 min, 81.7% within 1 h, and 92.9% within
2 h (Table 3).
Factors associated with a decreased likelihood of receiving
epinephrine in anaphylaxis included being <12 months of
age (OR 2.26, 95% CI 1.71–2.99), reported milk (OR 1.48,
95% CI 1.11–1.96) and egg (OR 1.52, 95% CI 1.01–1.27)
triggers, reporting at least one gastrointestinal symptom (OR
1.35, 95% CI 1.03–1.78), abdominal pain (OR 1.56, 95% CI
1.08–2.24), and diarrhea (OR 1.64, 95% CI 1.14–2.36). Fac-
tors associated with an increased likelihood of receiving epi-
nephrine for anaphylaxis included being a known asthmatic
(OR 1.39, 95% CI 1.01–1.90), reported peanut (OR 1.45,
95% CI 1.09–1.94), and tree nut (OR 1.50, 95% CI 1.02–
2.18) triggers, as well as most skin, mucosal, respiratory and
cardiovascular symptoms and signs. Reported wheat, soy,
ﬁsh or shellﬁsh triggers did not increase or decrease likeli-
hood of receiving epinephrine for anaphylaxis. The year in
which the reported index reaction occurred also did not affect
the likelihood of receiving epinephrine for anaphylaxis
(Table 4).
Antihistamines were used to treat most (93.1%) index
reactions, including 92.4% of those with likely anaphylaxis,
and 95.3% of those without likely anaphylaxis. Steroids were
additionally used in 81.6% of those reactions, including
80.8% of those reactions with likely anaphylaxis, and 84.5%
of those without anaphylaxis. Intravenous ﬂuids, respiratory
treatments and/or oxygen were administered in about two-
thirds of reactions. Less than 1% of reactions required intu-
bation. About 10% of reactions required admission to the
hospital, signiﬁcantly more for those with anaphylaxis
(12.0%) than those without anaphylaxis (3.2%) (p < 0.001).
Close to 3% of patients with likely anaphylaxis were admit-
ted to the intensive care unit, though none in those without
anaphylaxis (Fig. 2).
Discharge care and instructions for food allergy and anaphy-
laxis
Post-treatment in the subset of index reactions with anaphy-
laxis, 33.0% were prescribed epinephrine auto-injectors,
16.7% were trained to use epinephrine auto-injectors, and
7.5% were given epinephrine auto-injectors. Approximately
42.3% of anaphylaxis cases were referred to allergists. Less
34.3%
95% CI 31.3–37.3
339/988
7.7%
95% CI 4.7–10.7%
24/312
27.9%
95% CI 25.5–30.4%
363/1300
65.7%
95% CI 62.7–68.7%
649/988
92.3%
95% CI 89.3–95.3%
288/312
72.1%
95% CI 69.6–74.5%
937/1300
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
Anaphylaxis No anaphylaxis Total
Given epinephrine Not given epinephrine
Figure 1 Epinephrine given to patients with food-related allergic reactions with and without anaphylaxis (n = 1300).
Table 3 Timing of epinephrine given to patients of food-related
allergic reactions with and without anaphylaxis (n = 363)
Timing Anaphylaxis
n (cumulative %)
No anaphylaxis
n (cumulative %)
Total, n (%) 339 (93.4) 24 (6.6)
Median time
All providers 15–30 min 15–60 min
Parents Within 15 min Within 15 min
Paramedics 15–30 min Within 15 min
Primary care center 15–30 min Within 15 min
Urgent care center 30–60 min No observations
Emergency
department
30–60 min 30–60 min
Within 15 min 89 (26.3) 7 (29.2)
Within 30 min 93 (53.7) 5 (50.0)
Within 1 h 95 (81.7) 4 (66.7)
Within 2 h 38 (92.9) 5 (87.5)
Within 4 h 17 (97.9) 2 (95.8)
>4 h 7 (100.0) 1 (100.0)
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than one-quarter (19.1%) were given anaphylaxis emergency
medical plans. About one-third of anaphylactic reactions
were prescribed steroids (31.8%) and antihistamines (39.7%).
About one-tenth were prescribed bronchodilators (13.0%).
Of patients treated with epinephrine, less than half were pre-
scribed epinephrine auto-injectors (47.1%) (Table 5).
Discussion
In this study, we examined the management of anaphylaxis
in a group of patients at signiﬁcant risk for under-diagnosis
and treatment – children with ﬁrst-time reactions that require
medical evaluation before food allergies are formally
diagnosed. Our results suggest that anaphylaxis is under-
recognized and under-treated in patients without a prior food
allergy diagnosis. Only one-third of reported likely anaphy-
laxis cases were administered epinephrine. Post-treatment,
only one-third of patients with likely anaphylaxis were pre-
scribed epinephrine auto-injectors, and less than half were
referred to allergists. More than half of patients treated with
epinephrine were not prescribed epinephrine auto-injectors.
Our ﬁndings support prior studies suggesting that food-
induced anaphylaxis is often poorly recognized and under-
treated (17–23). Our ﬁndings again support a need for more
direct education regarding the broad diagnostic criteria of
anaphylaxis, given that the presentation can be subtle, lack
cutaneous symptoms, and not always be associated with car-
diovascular collapse. In a prior study of fatal and near-fatal
anaphylaxis cases in children, cutaneous symptoms and signs
were less common in food-induced anaphylaxis deaths com-
pared with those who survived (24). Many of the symptoms
and signs of anaphylaxis can be non-speciﬁc or misleading,
such as confusion, presyncope, collapse, or abdominal pain,
all of which carry broad differential diagnoses. Anaphylaxis
may be mistaken for an asthma exacerbation if signs of
cutaneous symptoms are overlooked, and/or if signs of car-
diovascular involvement are misattributed to side effects of
bronchodilator treatment. Anaphylaxis is likely under-diag-
nosed for these and a variety of other reasons (7, 19, 25–27).
Under-recognition and subsequent under-treatment of food-
related anaphylaxis may be particularly pronounced in the
pediatric population, especially in children presenting with
their ﬁrst episode of anaphylaxis. Previous reports show that
a large proportion of anaphylactic reactions had no previous
history of anaphylaxis or food allergies (22, 28).
Recognition of the variable and atypical presentations of
anaphylaxis is critical to providing frontline therapy with
intramuscular epinephrine, as well as reducing overreliance
on less-effective adjunctive medications as primary therapies,
such as antihistamines and glucocorticoids. Timely adminis-
tration of epinephrine is the only intervention that has been
shown to effectively treat the severity of the allergic reactions
(29, 30). Several case studies have implicated the failure of
rapid administration of epinephrine as a consistent ﬁnding in
anaphylaxis deaths (24, 31–37). Prior studies show that the
use of epinephrine is not consistent in both children and
adults and that physician knowledge of anaphylaxis manage-
ment guidelines is inadequate (20–22, 28, 38). Prompt, early
Table 4 Variables associated with under-treatment (no epineph-
rine) and variables associated with epinephrine treatment in cases
of food-related anaphylaxis (n = 988)
OR (95% CI)*
Variables associated with under-treatment (no epinephrine)
Demographic
Age <12 months 2.26 (1.71–2.99)
Inciting food (prior to event)
Milk 1.48 (1.11–1.96)
Egg 1.52 (1.01–2.27)
Symptoms
Having at least one gastrointestinal
symptom
1.35 (1.03–1.78)
Abdominal pain 1.56 (1.08–2.24)
Diarrhea 1.64 (1.14–2.36)
Variables associated with epinephrine treatment
Past medical history
Asthma 1.39 (1.01–1.90)
Inciting food (ingested prior to event)
Peanut 1.45 (1.09–1.94)
Treenut 1.50 (1.02–2.18)
Transport by ambulance 4.28 (3.07–5.96)
Symptoms
Skin symptoms
Facial erythema 1.49 (1.14–1.94)
Facial edema 2.07 (1.58–2.71)
Generalized hives 1.48 (1.13–1.93)
Generalized flushing 1.37 (1.05–1.78)
Swollen extremities 2.10 (1.41–3.11)
Generalized pruritus 1.35 (1.02–1.78)
Mucosal symptoms
Having at least one mucosal symptom 2.45 (1.70–3.54)
Angioedema 3.27 (2.49–4.30)
Eye symptoms 1.38 (1.06–1.80)
Dysphagia 2.93 (2.17–3.96)
Choking sensation 2.55 (1.87–3.47)
Respiratory symptoms
Having at least one respiratory symptom 2.54 (1.75–3.68)
Dysphonia 2.17 (1.57–3.00)
Cough 1.84 (1.41–2.40)
Dyspnea 2.79 (2.08–3.74)
Chest tightness 2.74 (1.79–4.20)
Noisy breathing 2.18 (1.67–2.85)
Cyanosis 2.38 (1.55–3.63)
Wheezing 2.35 (1.77–3.11)
Cardiovascular symptoms
Having at least one cardiovascular
symptom
2.35 (1.79–3.08)
Chest pain 4.40 (1.34–14.39)
Dizziness 1.84 (1.12–3.00)
Syncope 1.88 (1.02–3.47)
Diaphoresis 1.62 (1.03–2.53)
Palpitations 2.39 (1.17–4.92)
Confusion and mental status changes 2.02 (1.26–3.26)
Hypotension 2.43 (1.59–3.73)
Tachycardia 3.86 (2.56–5.82)
*OR was calculated using binary logistic regression.
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administration of epinephrine is a potentially modiﬁable fac-
tor in improving anaphylaxis survival.
In an effort to identify potential areas for educational and
therapeutic improvement, we identiﬁed risk factors for under-
treatment with epinephrine. Milk and egg allergies are more
common in infants and young children, and fatal milk aller-
gies affect mostly children (9, 10, 24, 32, 34, 39, 40). How-
ever, our study found that infancy, milk and egg triggers,
and reported gastrointestinal symptoms were independently
associated with anaphylaxis under-recognition and treatment.
Factors in our data set associated with an increased likeli-
hood of receiving epinephrine – asthma, and peanut and tree
nut allergies – correspond with well-established risk factors
for food-induced anaphylaxis and fatality (6, 24, 31–36, 39,
41).
There are several limitations of this study. Foremost, this
is a self-reported study assessing parental interpretation of a
reaction and its associated factors. However, studies of this
nature are routinely conducted as it is a practical and useful
way to assess food allergy in a large population. Another
notable limitation inherent to survey studies is recall bias. We
recognize that parents have varying levels of medical knowl-
edge and may not acknowledge certain medications, treat-
ments, or counseling provided especially under exigent
circumstances. To limit recall errors, we provided choices for
uncertainty. These responses were not included in proportion
estimates. With these acknowledged limits, a large proportion
of cases were identiﬁed as highly likely for food-induced ana-
phylaxis, using the NIAID/FAAN criteria. Some of this may
be explained by participation bias from respondents who had
a more severe event that they are less likely to overlook or
that may have been their motivation to take such a survey.
We have consistently labeled the reaction as ‘likely’ or ‘highly
likely’ for anaphylaxis, because we did not assess these
patients directly, and are relying on parental report of what
occurred, to account for biases in using these criteria. How-
ever, we highlight that such reports are no different from tak-
ing a history in the ofﬁce of a past event, which one also
would not have been able to assess. Additionally, prior less
severe reactions may have been self-treated and therefore
missed as the initial presentation of food allergy. A separate
analysis was performed limiting highly likely anaphylaxis to
those reactions that occurred within 1–2 h (we included all
cases in this analysis); the proportion estimates of likely ana-
phylaxis cases and epinephrine treatment did not signiﬁcantly
change. Because of this selection bias and intrinsic survey
study design, we acknowledge that the incidence of
2.2% (30/1361)
9.9% (135/1361)
0.6% (8/1361)
68.0% (925/1361)
69.5% (946/1361)
62.7% (853/1361)
81.6% (1111/1361)
93.1% (1267/1361)
27.9% (363/1300)
0.0% (0/317)
3.2% (10/317)
0.3% (1/317)
73.5% (233/317)
73.8% (234/317)
72.2% (229/317)
84.5% (268/317)
95.3% (302/317)
7.7% (24/312)
2.9% (30/1044)
12.0% (125/1044)
0.7% (7/1044)
66.3% (692/1044)
68.2% (712/1044)
59.8% (624/1044)
80.8% (843/1044)
92.4% (965/1044)
34.3% (339/988)
0.0% 20.0% 40.0% 60.0% 80.0% 100.0% 120.0%
Admission to ICU
Admission to hospital
Intubation
Oxygen
Respiratory treatment
Intravenous fluids
Steroids
Antihistamine
Epinephrine
Anaphylaxis No anaphylaxis Total
n = 1361n = 1044 n = 317
Figure 2 Medications, treatments and interventions provided to patients of food-related allergic reactions with and without anaphylaxis
(n = 1361).
Table 5 Discharge care and instructions provided to patients with
food-related anaphylaxis and those given epinephrine (treated as
anaphylaxis)
Discharge care and instructions Anaphylaxis
n (%)
Given epinephrine
n (%)
Total, n (%) 988 (76.0) 363 (27.9)
Given anaphylaxis emergency
action plan
199 (19.1) 98 (27.0)
Educated about biphasic reactions 204 (19.5) 125 (34.4)
Allergy referral 442 (42.3) 152 (41.9)
Prescribed epinephrine
auto-injectors
344 (33.0) 171 (47.1)
Given epinephrine auto-injectors 78 (7.5) 36 (9.9)
Trained to use epinephrine
auto-injectors
174 (16.7) 77 (21.2)
Prescribed steroids 332 (31.8) 185 (51.0)
Prescribed antihistamines 414 (39.7) 152 (41.9)
Prescribed bronchodilators 136 (13.0) 56 (15.4)
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anaphylaxis in ﬁrst-time food-induced allergic reactions
requiring medical care cannot be gathered from this study.
The parental survey design allowed for study beyond emer-
gency department management (to which retrospective chart
review designs were limited), but also included management
by other medical professionals often not part of the medical
record. It is clear from our study that emergency departments
were not the only location where initial anaphylaxis cases
presented. About 8% of epinephrine administration in ana-
phylaxis occurred in primary care physician ofﬁces. Only
about half of epinephrine administration in anaphylaxis
occurred in the emergency departments. In fact, the median
time to reported epinephrine administration was shorter in
primary care ofﬁces than in emergency departments.
We examined the management of ﬁrst-time food-related
reactions in children without prior diagnoses of food allergies
using a parental survey study design and found that anaphy-
laxis is under-recognized and under-treated. In this study,
only one-third of reported likely anaphylaxis cases were
administered epinephrine. These ﬁndings suggest that the
clinical presentation of a patient experiencing anaphylaxis is
often poorly recognized and that improved education and
awareness is necessary to raise the standard response to ana-
phylaxis at all provider levels.
References
1. Sampson HA, Munoz-Furlong A, Campbell
RL, et al. Second symposium on the
deﬁnition and management of anaphylaxis:
summary report – Second National Institute
of Allergy and Infectious Disease/Food
Allergy and Anaphylaxis Network sympo-
sium. J Allergy Clin Immunol 2006: 117:
391–7.
2. Sicherer SH, Sampson HA. 9. Food allergy.
J Allergy Clin Immunol 2006: 117 (2 Suppl.
Mini-Primer): S470–5.
3. Gupta RS, Springston EE, Warrier MR,
et al. The prevalence, severity, and distribu-
tion of childhood food allergy in the United
States. Pediatrics 2011: 128: e9–17.
4. Lieberman P, Nicklas RA, Oppenheimer J,
et al. The diagnosis and management of
anaphylaxis practice parameter: 2010
update. J Allergy Clin Immunol 2010: 126:
477–80, e1–42.
5. Kemp SF, Lockey RF. Anaphylaxis: a
review of causes and mechanisms. J Allergy
Clin Immunol 2002: 110: 341–8.
6. Sampson HA, Munoz-Furlong A, Bock SA,
et al. Symposium on the deﬁnition and man-
agement of anaphylaxis: summary report.
J Allergy Clin Immunol 2005: 115: 584–91.
7. Simons FE. Anaphylaxis, killer allergy:
long-term management in the community.
J Allergy Clin Immunol 2006: 117: 367–77.
8. Simons FE, Frew AJ, Ansotegui IJ, et al.
Risk assessment in anaphylaxis: current and
future approaches. J Allergy Clin Immunol
2007: 120 (1 Suppl.): S2–24.
9. Brown AF, McKinnon D, Chu K. Emer-
gency department anaphylaxis: a review of
142 patients in a single year. J Allergy Clin
Immunol 2001: 108: 861–6.
10. Sampson HA. Anaphylaxis and emergency
treatment. Pediatrics 2003: 111 (6 Pt 3):
1601–8.
11. Smit DV, Cameron PA, Rainer TH. Ana-
phylaxis presentations to an emergency
department in Hong Kong: incidence and
predictors of biphasic reactions. J Emerg
Med 2005: 28: 381–8.
12. Wang J, Sampson HA. Food anaphylaxis.
Clin Exp Allergy 2007: 37: 651–60.
13. Gupta R, Sheikh A, Strachan DP, Anderson
HR. Time trends in allergic disorders in the
UK. Thorax 2007: 62: 91–6.
14. Gupta R, Sheikh A, Strachan D, Anderson
HR. Increasing hospital admissions for sys-
temic allergic disorders in England: analysis
of national admissions data. BMJ 2003: 327:
1142–3.
15. Poulos LM, Waters AM, Correll PK,
Loblay RH, Marks GB. Trends in hospital-
izations for anaphylaxis, angioedema, and
urticaria in Australia, 1993–1994 to 2004–
2005. J Allergy Clin Immunol 2007: 120:
878–84.
16. Rudders SA, Banerji A, Vassallo MF, Clark
S, Camargo CA Jr. Trends in pediatric
emergency department visits for food-
induced anaphylaxis. J Allergy Clin Immunol
2010: 126: 385–8.
17. Decker WW, Campbell RL, Manivannan
V, et al. The etiology and incidence of
anaphylaxis in Rochester, Minnesota: a
report from the Rochester Epidemiology
Project. J Allergy Clin Immunol 2008: 122:
1161–5.
18. Lieberman P, Camargo CA Jr, Bohlke K, et
al. Epidemiology of anaphylaxis: ﬁndings of
the American College of Allergy, Asthma
and Immunology Epidemiology of Anaphy-
laxis Working Group. Ann Allergy Asthma
Immunol 2006: 97: 596–602.
19. Lin RY, Anderson AS, Shah SN, Nurruzz-
aman F. Increasing anaphylaxis hospitaliza-
tions in the ﬁrst 2 decades of life: New York
State, 1990–2006. Ann Allergy Asthma
Immunol 2008: 101: 387–93.
20. Clark S, Bock SA, Gaeta TJ, Brenner BE,
Cydulka RK, Camargo CA. Multicenter
study of emergency department visits for
food allergies. J Allergy Clin Immunol 2004:
113: 347–52.
21. Clark S, Camargo CA Jr. Emergency man-
agement of food allergy: systems perspective.
Curr Opin Allergy Clin Immunol 2005: 5:
293–8.
22. Russell S, Monroe K, Losek JD. Anaphy-
laxis management in the pediatric emergency
department: opportunities for improvement.
Pediatr Emerg Care 2010: 26: 71–6.
23. Moneret-Vautrin DA, Morisset M, Flabbee
J, Beaudouin E, Kanny G. Epidemiology of
life-threatening and lethal anaphylaxis: a
review. Allergy 2005: 60: 443–51.
24. Sampson HA, Mendelson L, Rosen JP.
Fatal and near-fatal anaphylactic reactions
to food in children and adolescents. N Engl
J Med 1992: 327: 380–4.
25. Brown SG. Clinical features and severity
grading of anaphylaxis. J Allergy Clin
Immunol 2004: 114: 371–6.
26. Mullins RJ. Anaphylaxis: risk factors for
recurrence. Clin Exp Allergy 2003: 33:
1033–40.
27. Simons FE. Anaphylaxis in infants: can rec-
ognition and management be improved? J
Allergy Clin Immunol 2007: 120: 537–40.
28. Novembre E, Cianferoni A, Bernardini R,
et al. Anaphylaxis in children: clinical and
allergologic features. Pediatrics 1998: 101:
E8.
29. Lane RD, Bolte RG. Pediatric anaphylaxis.
Pediatr Emerg Care 2007: 23: 49–56; quiz
57–60.
30. Lee JM, Greenes DS. Biphasic anaphylactic
reactions in pediatrics. Pediatrics 2000: 106:
762–6.
31. Pumphrey RS. Lessons for management of
anaphylaxis from a study of fatal reactions.
Clin Exp Allergy 2000: 30: 1144–50.
32. Bock SA, Munoz-Furlong A, Sampson HA.
Fatalities due to anaphylactic reactions to
foods. J Allergy Clin Immunol 2001: 107:
191–3.
33. Bock SA, Munoz-Furlong A, Sampson HA.
Further fatalities caused by anaphylactic
reactions to food, 2001–2006. J Allergy Clin
Immunol 2007: 119: 1016–8.
34. Pumphrey R. Anaphylaxis: can we tell who
is at risk of a fatal reaction? Curr Opin
Allergy Clin Immunol 2004: 4: 285–90.
35. Pumphrey RS, Gowland MH. Further fatal
allergic reactions to food in the United
A survey study of anaphylaxis management Jacobs et al.
588 Pediatric Allergy and Immunology 23 (2012) 582–589 ª 2012 John Wiley & Sons A/S
Kingdom, 1999–2006. J Allergy Clin Immu-
nol 2007: 119: 1018–9.
36. Greenberger PA, Rotskoff BD, Lifschultz B.
Fatal anaphylaxis: postmortem ﬁndings and
associated comorbid diseases. Ann Allergy
Asthma Immunol 2007: 98: 252–7.
37. Anchor J, Settipane RA. Appropriate use of
epinephrine in anaphylaxis. Am J Emerg
Med 2004: 22: 488–90.
38. Beno SM, Nadel FM, Alessandrini EA. A
survey of emergency department manage-
ment of acute urticaria in children. Pediatr
Emerg Care 2007: 23: 862–8.
39. Webb LM, Lieberman P. Anaphylaxis: a
review of 601 cases. Ann Allergy Asthma
Immunol 2006: 97: 39–43.
40. Braganza SC, Acworth JP, McKinnon DR,
Peake JE, Brown AF. Paediatric emergency
department anaphylaxis: different patterns
from adults. Arch Dis Child 2006: 91: 159–63.
41. Lieberman P. Biphasic anaphylactic reac-
tions. Ann Allergy Asthma Immunol 2005:
95: 217–26; quiz 226, 258.
Jacobs et al. A survey study of anaphylaxis management
Pediatric Allergy and Immunology 23 (2012) 582–589 ª 2012 John Wiley & Sons A/S 589
